According to the next month’s update for the pharmaceutical reimbursement list, total five items would be newly listed and improve patient access. And one already-listed drug gets to expand coverage. It is a result of enhancing the coverage based on social importance and patient needs.

The South Korean government projected total 60,196 patients in the country would benefit from those drugs, costing them about 51.4 billion won annually.

From January through April this year, total six pharmaceutical products have been newly listed or expanded coverage standard.

January had none, but from February, the coverage on a Parkinson’s disease treatment Equfina Film Coated Tablet,